COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico

Castano-Jaramillo, Lina M.; Yamazaki-Nakashimada, Marco Antonio; O’Farrill-Romanillos, Patricia M.; Muzquiz Zermeño, David; Scheffler Mendoza, Selma C.; Venegas Montoya, Edna; García Campos, Jorge Alberto; Sánchez-Sánchez, Luz María; Gámez González, Luisa B.; Ramírez López, Jesús Moisés; Bustamante Ogando, Juan Carlos; Vásquez-Echeverri, Estefanía; Medina Torres, Edgar Alejandro; Lopez-Herrera, Gabriela; Blancas Galicia, Lizbeth; Berrón Ruiz, Laura; Staines-Boone, Aidé Tamara; Espinosa-Padilla, Sara Elva; Segura Mendez, Nora Hilda; Lugo Reyes, Saul O.

INTRODUCTION: Patients with inborn errors of immunity (IEI) have a compromised or inappropriate immune response. Although they might be considered a high-risk group for severe SARS-CoV-2 infection, the reported impact of COVID-19 in these patients has been reassuring, while the differential susceptibility of distinct types of IEI remains unclear. OBJECTIVE: We aimed to describe the findings and outcomes of our known patients with IEI who were diagnosed with COVID-19. METHODS: In a retrospective study from March 2020 to February 2021, four centers in Mexico collected clinical, laboratory, and genetic data from pediatric and adult patients with known diagnoses of IEI who presented with COVID-19, based on compatible symptoms and positive SARS-CoV-2 testing or known household exposure. RESULTS: We report 31 patients with known IEI from Mexico who presented with SARS-CoV-2 infection. Seventy-four percent were male, 52% were pediatric, and 81% survived. Their ages ranged from 5 months to 56 years, with a median of 17 years. Sixty-five percent had predominant antibody deficiencies, 48% were hospitalized, and 26% required ICU. Pediatric patients had a higher hospital admission rate than adults. Inpatient mortality was 40%, and ICU mortality rate was 63%. Forty-eight percent developed pneumonia, while 36% had evidence of hyperinflammation (4 adults and 7 children). Predominant laboratory features were lymphopenia and thrombocytopenia, seen in 70 and 44% of patients, respectively. The serum D-dimer median value was 2.6 (0.5–20.6) μg/mL, and the median highest ferritin value was 1015 (32–10,303) ng/mL. Intravenous immunoglobulin was used in 80% of patients. Other treatments included macrolides (39%) and corticosteroids (29%). Six patients died from secondary infection or uncontrolled systemic inflammation. DISCUSSION: Although impaired immunity due to IEI may be a predisposing factor for severe COVID-19, most of our patients with IEI who acquired the SARS-CoV-2 infection developed a well-tolerated infection and survived, as have more than 80% of worldwide reported patients to date. An impaired immune or inflammatory response may be a predisposing factor for some and a protective factor for others. A systematic review of the literature could help identify those patients at risk of severe disease and complications. Healthcare-associated infections should be aggressively prevented.